Evidence map›Paper›PMID 35189948›Full record

Observational studyOrphanet journal of rare diseases2022

Eight months follow-up of corneal nerves and sensitivity after treatment with cenegermin for neurotrophic keratopathy.

Emilio Pedrotti, Erika Bonacci, Chiara Chierego, Alessandra De Gregorio, Tiziano Cozzini, Tommaso Brighenti, Grazia Caldarella, Giovanlorenzo Pastore, Adriano Fasolo, Giorgio Marchini

Open access · goldAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Orphanet journal of rare diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
7.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 39 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Non-contact confocal calcium imaging ofBiomedical optics express · 2025
    Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. A Vicious NGF-p75International journal of molecular sciences · 2023
    Article
  15. Article
  16. Article
  17. A, B, C's of Trk Receptors and Their Ligands in Ocular Repair.International journal of molecular sciences · 2022
    Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Emilio PedrottiOphthalmic Unit, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Policlinico G.B. Rossi, P.Le L.A, Scuro 10, 37134, Verona, VR, Italy.
Erika BonacciOphthalmic Unit, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Policlinico G.B. Rossi, P.Le L.A, Scuro 10, 37134, Verona, VR, Italy.
Chiara ChieregoOphthalmic Unit, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Policlinico G.B. Rossi, P.Le L.A, Scuro 10, 37134, Verona, VR, Italy.
Alessandra De GregorioOphthalmic Unit, San Bassiano Hospital, Via dei Lotti, 40, 36061, Bassano del Grappa, Italy.
Tiziano CozziniOphthalmic Unit, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Policlinico G.B. Rossi, P.Le L.A, Scuro 10, 37134, Verona, VR, Italy. tizianocozzini@gmail.com.ORCID 0000-0001-9183-2379
Tommaso BrighentiOphthalmic Unit, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Policlinico G.B. Rossi, P.Le L.A, Scuro 10, 37134, Verona, VR, Italy.
Grazia CaldarellaOphthalmic Unit, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Policlinico G.B. Rossi, P.Le L.A, Scuro 10, 37134, Verona, VR, Italy.
Giovanlorenzo PastoreOphthalmic Unit, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Policlinico G.B. Rossi, P.Le L.A, Scuro 10, 37134, Verona, VR, Italy.
Adriano FasoloOphthalmic Unit, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Policlinico G.B. Rossi, P.Le L.A, Scuro 10, 37134, Verona, VR, Italy.
Giorgio MarchiniOphthalmic Unit, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Policlinico G.B. Rossi, P.Le L.A, Scuro 10, 37134, Verona, VR, Italy.
University of Verona · ITOspedale San Bassiano · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroudCenegermin (Oxervate, Dompè Farmaceutici, Milan, IT), a recombinant human NGF, is a potentially healing new drug for neurotrophic keratopathy (NK), a rare but challenging disease affecting the cornea. To date, studies that evaluate its mid-term effect on corneal nerves and sensitivity are lacking.

objectiveTo evaluate the recovery and morphology of subbasal corneal nerves in patients treated with Cenegermin for NK and assess their correlation with corneal sensitivity.

methodsThis prospective, observational case series study was carried out between May 2018 and August 2020 at the Ophthalmic Clinic of the University of Verona. Clinical evaluation, sensitivity, and in vivo confocal microscopy (IVCM) were performed in the central and all four corneal sectors at baseline, the end of therapy (8 weeks), and 2, 4, and 8 months after therapy. Consecutive patients with NK (stage 2-3), treated with Cenegermin (1 drop 6 times daily for 8 weeks), were enrolled. During each visit, Corneal nerve fiber length (CNFL), corneal nerve fiber total branch density (CTBD), corneal nerve fiber fractal dimension (CNFraD) and Cochet-Bonnet esthesiometry (CBE) were measured.

resultsWe enrolled 18 patients. Complete NK healing was noted in 14/18(78%) patients after 8 weeks of treatment; then in 14(78%), 15(83%), and 13(72%) patients at 2-, 4-, and 8-months, respectively. Starting at 8 weeks through 4-month follow-up there was progressive improvement in CBE in all corneal sectors (p ≤ 0.01), which continued thereafter. There was significant corneal nerve regrowth especially in the peripheral cornea: centripetal progression starting at 8 weeks (CNFL and CNFrad) and significant branching starting at 2 months (CTBD), which continued through to the end of follow up. Sector-coupled IVCM and CBE findings correlated at all evaluations (all r ≥ 0.62 starting at 2 months, with highest values in the peripheral sectors).

conclusionsAfter Cenegermin we observed a subbasal corneal nerve regeneration, a recovery of sensitivity and a lasting epithelial healing, suggesting that the effect of its action persists several months after discontinuation in patients with NK.

Indexed as

Corneal Dystrophies, HereditaryNerve Growth FactorCorneaFollow-Up StudiesHumansOphthalmic SolutionsProspective StudiesRecombinant ProteinscenegerminNerve Growth FactorOphthalmic SolutionsRecombinant ProteinsCenegerminCorneal nervesCorneal sensitivityIn vivo confocal microscopyNerve growth factorNeurotrophic keratopathyrhNGF

Identifiers

PMID35189948
PMCPMC8862484
OpenAlexW4213205662

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.